<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67717">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02224287</url>
  </required_header>
  <id_info>
    <org_study_id>P00003145</org_study_id>
    <nct_id>NCT02224287</nct_id>
  </id_info>
  <brief_title>Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control</brief_title>
  <official_title>Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective randomized trial to study the effect of assigning the control of the
      fluoroscopic x-ray activation to the surgeon as compared to the radiation technologist.
      Radiation exposure will be assessed from the collected data, fluoroscopy time, and dose
      parameters (cumulative absorbed dose and dose area product). From exposure data, entrance
      skin dose (ESD) and midline absorbed dose (MLD) will be calculated. The primary outcome in
      this study will be total fluoroscopy time for the procedure. A secondary outcome will be the
      ESD. The investigators will further analyze the contribution of clinical predictors (e.g.
      stone size/location) and procedural predictors on fluoroscopy times and ESD.

      It is hypothesized that a 30% reduction in fluoroscopy time will occur when the operating
      surgeon is controlling the activation of the x-ray beam.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome in this study will be total fluoroscopy time for the procedure.</measure>
    <time_frame>1-5 hours</time_frame>
    <description>The average duration of a ureteroscopy is 1-5 hours. At the completion of the surgery, the individual outcomes will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary outcome will be the entrance skin dose (mGy). We will further analyze the contribution of clinical predictors (e.g. stone size/location) and procedural predictors on fluoroscopy times and entrance skin dose.</measure>
    <time_frame>1-5 hours</time_frame>
    <description>The average duration of a ureteroscopy is 1-5 hours. At the completion of the surgery, the individual outcomes will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Urolithiasis</condition>
  <condition>Kidney Stones</condition>
  <arm_group>
    <arm_group_label>Fluoroscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Technologist control of fluoroscopy Surgeon control of fluoroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Technologist control of fluoroscopy</intervention_name>
    <description>Technologist control of fluoroscopy</description>
    <arm_group_label>Fluoroscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgeon control of fluoroscopy</intervention_name>
    <description>Surgeon control of fluoroscopy</description>
    <arm_group_label>Fluoroscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing ureteroscopy for urolithiasis

          -  5 years to 25 years old

        Exclusion Criteria:

          -  Pregnant

          -  Less than 5 years old or older than 25 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caleb Nelson, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Migliozzi, MA</last_name>
    <phone>617-355-3559</phone>
    <email>Matthew.Migliozzi@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Matero</last_name>
      <phone>617-919-4229</phone>
      <email>Catherine.matero@childrens.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 24, 2016</lastchanged_date>
  <firstreceived_date>August 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Caleb Nelson</investigator_full_name>
    <investigator_title>Caleb Nelson MD, MPH</investigator_title>
  </responsible_party>
  <keyword>Urolithiasis</keyword>
  <keyword>Kidney Stones</keyword>
  <keyword>Ureteroscopy</keyword>
  <keyword>Fluoroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
